Instead, available therapies target HBV DNA suppression, HBeAg and HBsAg loss/seroconversion, and normalization of alanine aminotransferase (ALT) levels to prevent disease progression and development of HCC and improve patient-oriented outcomes, including survival and quality of life. The gene discussed is GPT; the disease is hepatocellular carcinoma.